Tryp Therapeuatics (TRYPF) Coverage Report

Exhibit 16: Subjective effects of psilocybin Ratings of psychometric scale items performed within 15 min of participants exiting the scanner after both sessions. Items were completed using a visual analog scale format, with a bottom anchor of “no, not more than usually” and a top anchor of “yes, much more than usually” for every item, with the exception of “I felt entirely normal,” which had bottom and top anchors of “No, I experienced a different state altogether” and “Yes, I felt just as I normally do,” respectively. Shown are the mean ratings for 15 participants plus the positive SEMs. All items marked with an asterisk were scored significantly higher after psilocybin than placebo infusion. Source: J Neurosci. 2013; 33(38): 15171 1. Psilocybin’s effects on the body. Psilocybin can also produce acute adverse physical effects on different systems in the body (Exhibit 16B). In human studies, the onset of autonomic and psychological effects generally started within 30 min of oral ingestion, peaking within one to two hours, and decreasing over the next few hours Molecules. 2021 May 15;26(10):2948). Effects such as dizziness, nausea, weakness, muscle aching, shivering, abdominal pain and dilation of pupils (mydriasis) are not very significant. Tachycardia and an increase in both systolic and diastolic blood pressure is observed after a 0.2 mg/kg psilocybin oral dose. It is important to note that psilocybin can also temporarily elevate the blood pressure and therefore could be limited in individuals with cardiovascular issues. Adverse effects such as, severe stomach pain, persistent vomiting, diarrhea have been reported but are believed to be related to the ingestion of mushrooms (Regul Toxicol Pharmacol. 2011;59(3): 423). Exhibit 16B: Acute toxic effects Source: Drug Metab Rev. 2017; 49(1): 84 Body systems Adverse effects Cardiovascular Tachycardia, hypertension, and hypotension Neurological Headache, confusion, euphoria, muscle weakness, hallucinations, panic attacks, derealization, illusions, synesthesia, convulsions, alterations of thought and time sense, vertigo, anxiety, agitation Respiratory Transient hypoxemia Gastrointestinal Nauseas Renal Acute renal failure Ocular Mydriasis Michael Higgins 212.409.2074 Tryp Therapeutics, Inc. (TRYPF) Page 23